Invention Grant
- Patent Title: TGFβ receptor antagonist
-
Application No.: US15746597Application Date: 2016-07-21
-
Publication No.: US10336761B2Publication Date: 2019-07-02
- Inventor: Lalgudi S. Harikrishnan , Brian E. Fink , Robert M. Borzilleri , Gopikishan Tonukunuru , Hasibur Rahaman , Jayakumar Sankara Warrier , Balaji Seshadri
- Applicant: BRISTOL-MYERS SQUIBB COMPANY
- Applicant Address: US NJ Princeton
- Assignee: Bristol-Myers Squibb Company
- Current Assignee: Bristol-Myers Squibb Company
- Current Assignee Address: US NJ Princeton
- Agent Elliott Korsen
- International Application: PCT/US2016/043252 WO 20160721
- International Announcement: WO2017/015425 WO 20170126
- Main IPC: A61K31/53
- IPC: A61K31/53 ; A61K31/541 ; C07D487/04
Abstract:
The invention relates generally to compounds that modulate the activity of TGFβR-1 and TGFβ R-2, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.
Public/Granted literature
- US20180215761A1 TGF BETA RECEPTOR ANTAGONISTS Public/Granted day:2018-08-02
Information query
